Hemophilia B Treatment Options

While hemophilia B cannot be cured, it can be treated and managed successfully. The two main types of treatment for hemophilia B are replacement therapy, which helps increase the level of factor IX in the blood, and the use of local clotting agents. Local clotting agents help protect blood clots and keep them in place to stop bleeding.

Replacement Therapy

In general, small cuts and scrapes are treated with typical first-aid: clean the cut, apply pressure and cover with a band-aid. People with mild hemophilia can use a non-blood product called desmopressin acetate (DDAVP) to treat mild bleeds. More complex treatment will be required for deep cuts or internal bleeding, such as bleeding into the joints or muscles. The missing clotting factor (VIII or IX) must be replaced so the child can form a clot to stop the bleeding. The main goal is to increase or replace the level of factor IX in the blood.

Some factor products are made from human blood products, such as donated plasma. Others, called "recombinant factor," are made in a laboratory and do not use human blood products. The Medical and Scientific Advisory Council of the National Hemophilia Foundation encourages the use of recombinant clotting factor products because they are safer. All factor treatments are injected or infused directly into the veins.

Factor IX concentrates are the typical course of therapy for hemophilia B. However, in cases of severe hemophilia, doctors sometimes recommend a regimen of regular factor replacement treatments. This is called prophylaxis, and it prevents bleeding episodes before they occur.

From CSL Behring, Coagulation Factor IX (Human), Mononine^® is indicated for the prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease.

Learn more about Mononine

Important Safety Information About Mononine

Mononine is indicated for the prevention and control of bleeding in Factor IX deficiency, also known as Hemophilia B or Christmas disease.

Mononine is not indicated in the treatment or prophylaxis of Hemophilia A patients with inhibitors to Factor VIII.

Mononine is contraindicated in patients with known hypersensitivity to mouse protein.

The following adverse reactions may be observed after administration: headache, fever, chills, flushing, nausea, vomiting, tingling, lethargy, hives, stinging or burning at the infusion site, or other manifestations of allergic reactions, including anaphylaxis.

Mononine is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Since the use of Factor IX Complex concentrates has historically been associated with the development of thromboembolic complications, the use of Factor IX-containing products may be potentially hazardous in patients with signs of fibrinolysis and in patients with disseminated intravascular coagulation (DIC).

Please see full prescribing information for Mononine.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.